Sitemap

Prognostic Score of Tsimberidou et al for a Patient with Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma (University of Texas M.D. Anderson Cancer Center Score)

Correlating the Response to Rituximab Therapy for a Patient with Chronic Lymphocytic Leukemia (CLL) with the FISH Subtype

Risk Factors of Nowakowski et al Affecting Survival in a Patient with Chronic Lymphocytic Leukemia (CLL)

Prognostic Index of Wierda et al for a Patient with Chronic Lymphocytic Leukemia (CLL)

Therapy Independent Nomogram of Wierda et al for Evaluating a Previously Untreated Patient with Chronic Lymphocytic Leukemia (CLL)

Therapy Inclusive Nomogram of Wierda et al for Evaluating a Previously Untreated Patient with Chronic Lymphocytic Leukemia (CLL)

Prognostic Classification of Dighiero and Hamblin for Chronic Lymphocytic Leukemia

Risk Factors of Francis et al for Major Infections in a Patient with Chronic Lymphocytic Leukemia (CLL)

Indolent Mantle Cell Leukemia

Model of Wierda et al for Time to First Treatment in a Patient with Chronic Lymphocytic Leukemia (CLL)

Scoring System of Matutes et al for Immunophenotyping Hairy Cell Leukemia (HCL)

Bone Marrow Fibrosis in a Patient with Chronic Lymphocytic Leukemia (CLL)

Chronic Lymphocytic Leukemia with Prolymphocytoid Transformation (CLL/PL)

Findings Associated with a Poor Prognosis in a Patient with Chronic Lymphocytic Leukemia (CLL)

Algorithm of Siddon et al for Treating a Patient with CLL

Prognostic Factors of Nowakowski et al for a Patient with Chronic Lymphocytic Leukemia (CLL)

Prognostic Factors in Acute Myeloid Leukemia

French-American-British (FAB) Classification of Acute Myeloid Leukemia

Subclassification of Erythroleukemia

Prognostic Groups of Estey for Acute Myelogenous Leukemia (AML)

Distinguishing Acute Promyelocytic Leukemia (APML) from the Recovery Phase of Acute Agranulocytosis Using CD117 and CD11b Immunostaining of the Bone Marrow

Prognostic Index of Breems et al (European Prognostic Score) for an Adult Patient with Acute Myelogenous Leukemia (AML) in the First Relapse

Risk Groups of Giles et al in Patients with Acute Myelogenous Leukemia After Second Salvage Therapy

Mortality Risk Factors of Creutzig et al in Children Treated for Acute Myeloid Leukemia (AML) in the Berlin-Frankfurt-Muenster (BFM) Trials 93 and 98

Prognostic Score of Jourdan et al for a Young Adult with Acute Myeloblastic Leukemia in First Complete Remission and without a Donor for Allogeneic Stem Cell Transplantation

Risk Factors of Johnston et al for an Isolated CNS Relapse in a Pediatric Patient with Acute Myeloid Leukemia

Risk Factors for the Development of Acute Myeloid Leukemia

Model of Kantarjain et al for Predicting Complete Response in a Patient >= 65 Years Old Treated with Intensive Chemotherapy for Acute Myelogenous Leukemia or High-Risk Myelodysplastic Syndrome

Model of Kantarjain et al for Predicting Induction Mortality and Overall Survival in a Patient >= 65 Years Old Treated with Intensive Chemotherapy for Acute Myelogenous Leukemia or High-Risk Myelodysp

Prognostic Factors of Razzouk et al for a Child with Acute Myeloid Leukemia (AML)

Model of Johnson et al for Predicting Survival for an Elderly Patient with Acute Myeloid Leukemia (AML)

Model of Estey et al for Predicting Survival During Induction Therapy in a Patient Newly Diagnosed with Acute Myeloblastic Leukemia (AML)

Prognostic Factors of Rubnitz et al for a Pediatric Patient with Recurrent Acute Myeloid Leukemia

Prognostic Factors of Etienne et al for Complete Remission in an Elderly Patient Receiving Induction Chemotherapy for Acute Myeloid Leukemia (AML)

Auer Rods versus Pseudo-Auer Rods

Risk Model of Sorror et al for a Patient with Acute Myeloid Leukemia or Myelodysplasia Following Allogeneic Hematopoietic Cell Transplantation

Clinical and Laboratory Features of the Microgranular or Hypogranular Variant of Acute Promyelocytic Leukemia (M3v)

Prognostic Score of Haferlach et al for Acute Myeloid Leukemia (AML)

Model of Sanz et al for Risk of Relapse in a Patient with Acute Promyelocytic Leukemia

Prognostic Factors of Harb et al for a Patient Greater Than or Equal to 80 Years of Age with Acute Myeloid Leukemia

Immunohistochemical Algorithm of Cronin et al for Diagnosis of Myeloid Leukemia Cutis

Acute Myeloid Leukemia in a Patient with Down's Syndrome (Trisomy 21)

Activity of the Renin-Angiotensin System (RAS) in Acute Myeloid Leukemia

Prognostic Factors of Knipp et al for a Patient More Than 60 Years of Age with Acute Myeloid Leukemia or Myelodysplasia

Response Criteria Following Therapy of Acute Myeloid Leukemia (AML)

Criteria for Relapse of Acute Myeloid Leukemia (AML) Following Remission

Impact of Age and DNMT3A Mutation Status on Survival for a Patient with Acute Myeloid Leukemia (AML)

Acute Myeloid Leukemia (AML) with Cytogenetic Abnormalities at 3q21q26

Prognostic Factors of Kurosawa et al Affecting Survival for a Patient with Acute Myeloid Leukemia (AML) After First Relapse

Scoring System of Valcarcel et al for Predicting Death During Induction Therapy for Acute Myelogenous Leukemia (AML)

Basic Model of Walter et al for Predicting Early Death After Induction Therapy for Newly Diagnosed Acute Myeloid Leukemia (AML)

Complex Model of Walter et al for Predicting Early Death After Induction Therapy for Newly Diagnosed Acute Myeloid Leukemia (AML)

Prognostic Score of Malagola et al for Cytogenetically Normal Acute Myeloid Leukemia (CN-AML)

Risk Factors of Mailankody et al for Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS) Occurring in a Patient with Multiple Myeloma or Monoclonal Gammopathy of Unknown Significance (MGUS)

Criteria of de Greef et al for Complete Remission in Acute Myeloid Leukemia (AML)

Features of Immunomodulator Agent-Related Lymphoproliferative Disorders Reported By Hasserjian et al

Methotrexate-Associated Lymphoproliferative Disorder

Phenytoin-Induced Pseudolymphoma

Lymphoma Associated with Phenytoin Therapy (Pseudo-Pseudolymphoma)

Diagnosis of Monoclonal Gammopathies

Myeloma Staging System of Durie and Salmon

Myeloma Staging System of Carbone et al

Myeloma Staging System of British Medical Research Council

Myeloma Staging System of Alexanian et al

Myeloma Staging System of Southeastern Cancer Study Group

Myeloma Staging System of ALGB and ECOG

Criteria for the POEMS Syndrome

Myeloma Staging System of Pasqualetti et al

Criteria of the Chronic Leukemia-Myeloma Task Force for Evaluating the Response of Multiple Myeloma to Therapy

Myeloma Staging System of Durie and Salmon Supplemented with MRI

International Staging System of the International Myeloma Working Group (Greipp et al) for Multiple Myeloma

Prognostic Factors of Weber et al for Progression in Asymptomatic Multiple Myeloma

Risk Stratification Model of Weber et al Predicting Progression in Asymptomatic (Smoldering) Multiple Myeloma

Prognostic Factors of Rajkumar et al for Progression in a Patient with Monoclonal Gammopathy of Undetermined Significance (MGUS)

Features of Solitary Plasmacytoma

Staging System of the Southwest Oncology Group (SWOG) for a Patient with Multiple Myeloma

Diagnostic Algorithm of Shaw for Nonsecretory Plasma Cell Myeloma

Prognostic Groups of Kyle et al for Patients with Smoldering (Asymptomatic) Multiple Myeloma

Hyperammonemia in a Patient with Multiple Myeloma

Prognostic Factors of Hillengass et al for a Patient with Asymptomatic Multiple Myelomas, Including Focal Lesions in Bone Detected by Whole Body MRI

Bone Marrow Staging System of Allawadhi et al for Multiple Myeloma Based on MRI Involvement (BM-MRI)

Plasma Cell Leukemia

Multiple Myeloma: Beta-2 Microglobulin and Serum Albumin

Multiple Myeloma: Telopeptide

Multiple Myeloma: Labelling Index (LI)

Multivariate Analysis with Plasma Cell Morphology

Histologic Grading of Plasma Cell Dysplasia in Multiple Myeloma

Molecular Markers Used at the Mayo Clinic to Identify High-Risk Multiple Myeloma

Criteria of Greipp et al for Myeloma Cell Typing and Myeloma Classification

Light Chain Monoclonal Gammopathy of Undetermined Significance (LC-MGUS)

Significance of Immunostaining a Bone Marrow Biospy Containing Plasma Cells with CD56 (NCAM)

Model of Rossi et al for Predicting the Risk of Progression in a Patient with Asymptomatic Multiple Myeloma

The TEMPI Syndrome

Crystalglobulinemia Syndrome (Crystal-Induced Vasculopathy in Multiple Myeloma)

Model of Schaefer et al for Correlating Prognosis with the Reduction in Serum Monocloncal Protein During Chemotherapy

Staging System of Dispenzieri et al for Primary Systemic Amyloidosis Based on Cardiac Troponin and pro-BNP Serum Levels

Risk Score of Dispenzieri et al for Primary Systemic Amyloidosis

Unfavorable Prognostic Factors of Kyle et al for a Patient with Primary Amyloidosis

Prognostic Factors of Moreau et al for Survival After Autologous Stem Cell Transplantation of a Patient with Systemic AL Amyloidosis

Risk Groups of Kyle et al for Survival in Patients with Primary Systemic Amyloidosis

Criteria of Gertz et al for Therapeutic Response in a Patient with Primary Systemic Amyloidosis

Criteria of Kyle et al for Therapeutic Response in a Patient with Primary Systemic Amyloidosis

Clinical Findings That Should Alert the Clinician to the Possibility of Amyloidosis

Early Mortality Risk Score of Kumar et al for a Patient with Primary Systemic Amyloidosis

Clinical Features of Dialysis-Associated Amyloidosis (Beta-2 Microglobulin Amyloidosis)

Revised Prognostic Staging System of Kumar et al for a Patient with Light Chain (Primary Systemic) Amyloidosis

Ann Arbor Stages of Non-Hodgkin's Lymphoma (Including B Symptoms)

Histologic Grading of Follicular Lymphomas

Prognostic Factors in Aggressive Malignant Lymphomas

International Prognostic Index (IPI) and Prognosis in Aggressive Non-Hodgkin's Lymphoma

Prognosis in Intermediate and High Grade Non-Hodgkin's Lymphoma

Prognostic Factors in Aggressive Diffuse Non-Hodgkin's Lymphoma Before Therapy

Risk Classification of Velasquez et al for Clinical Staging of Diffuse Large Cell Lymphoma

Serologic Staging System for Diffuse Large Cell Non-Hodgkin's Lymphoma Using Initial Serum Lactate Dehydrogenase and beta-2-Microglobulin Levels

Prognostic Model of Federico et al for Follicular Lymphoma (Italian Lymphoma Intergroup Index)

The University of Texas M.D. Anderson Cancer Center's Tumor Score for Aggressive Lymphoma

Prognostic Factors of Wilder et al for Patients with Aggressive Lymphoma

Memorial Sloan Kettering Cancer Center Predictive Model for Advanced Diffuse Histiocytic Lymphoma

Prognostic Subgroups of Shipp et al for Diffuse Large Cell Lymphoma

1976 SWOG Criteria for Response of Non-Hodgkins Malignant Lymphoma to Therapy

St. Jude Staging System for Burkitt's Lymphoma (Murphy Staging System)

Prognostic Factors in Burkitt's Lymphoma

Diagnostic Features of Microvillous Lymphomas

Prognostic Score of Ferreri et al for Primary CNS Lymphoma (IELSG Score)

Prognostic Factors of Dumontet et al for Death During Induction Chemotherapy in Patients with Aggressive Non-Hodgkin's Lymphoma

Prognostic Factors of Arcaini et al for Survival in Patients with Marginal Zone Lymphomas

Prognostic Factors of International Extranodual Lymphoma Study Group (IELSG) al for a Male with Diffuse Large Cell Lymphoma of the Testis

Prognostic Factors of Chacon et al for Patients with Splenic Marginal Zone Lymphoma

Criteria of Chacon et al for Therapeutic Response in Patients with Splenic Marginal Zone Lymphoma

Prognostic Model of Lossos et al in Diffuse Large B-Cell Non-Hodgkin's Lymphoma Using a Panel of 6 Genes

Criteria of Loggins and Urquhart for Suspecting Non-Hodgkin's Lymphoma in a Patient With a Parotid Mass

Risk Factors of Stebbing et al for Non-Hodgkin's Lymphoma in a Patient with HIV Infection

Standardized Response Criteria of Cheson et al for Therapy in Non-Hodgkin's Lymphoma

Prognostic Factors of Mournier et al from the Groupe d'Etuda des Lymphomes de l'Adulte (GELA) for Patients with Aggressive Non-Hodgkin's Lymphoma Treated by Autologous Stem Cell Transplantation (ASCT)

Risk Factors of Voulgarelis and Moutsopoulos for Development of Malignant Lymphoma in a Patient with Sjogren's Syndrome

Criteria for T-Cell Rich, Histiocyte Rich Diffuse Large B-Cell Non-Hodgkin's Lymphoma

Prognostic Factors of Shenkier et al for an Immunocompetent Patient with a Primary Central Nervous System Lymphoma

Prognostic Factors of Shenkier et al for a Patient with a Primary T Cell Central Nervous System Lymphoma

The Follicular Lymphoma International Prognostic Index (FLIPI)

Immunophenotypic Markers of Berglund et al Associated with Prognosis for a Patient with Diffuse Large B-Cell Lymphoma

Prognostic Factors of Hui et al for a Patient with Mantle Cell Lymphoma

Prognostic Factors of Suzuki et al for a Patient with Blastic Natural Killer Cell (NK-Cell) Lymphoma/Leukemia

Diagnostic Features of Blastic Natural Killer Cell (NK-Cell) Lymphoma/Leukemia

Criteria of Boulanger et al for the Diagnosis of a Primary Effusion Lymphoma Associated with Human Herpesvirus 8 (HHV-8)

Prognostic Factors of Boulanger et al for AIDS-Associated Primary Effusion Lymphoma (PEL)

Risk Factors of Lyman et al for the Failure to Adequately Treat a Patient with an Aggressive Non-Hodgkin's Lymphoma

Clinical Features of Intravascular Anaplastic Large Cell Malignant Lymphoma

Prognostic Model of Lee et al for Extranodal Natural Killer/T (NK/T) Cell Lymphoma of the Nasal Type (Korean Prognostic Index, KPI)

Guidelines of the International Primary CNS Lymphoma Collaborative Group for Therapeutic Response

Clinical-Pathologic Prognostic Score of Went et al for a Patient with Peripheral T-Cell Lymphoma

Prognostic Model of Gallamini et al for a Patient with a Peripheral T-Cell Lymphoma Unspecified (PTCL-U)

Prognostic Model of Hoskins et al for a Patient with Diffuse Large Cell Lymphoma Treated with MACOP-B

Risk Factors of Smedby et al for Malignant Non-Hodgkin Lymphoma in a Patient with Rheumatoid Arthritis

Prognostic Factors of Lim et al for HIV-Related Diffuse Large-Cell Non-Hodgkin's Lymphoma

Prognostic Model of Arcaini et al for a Splenic Marginal Zone Lymphoma (Intergruppo Italiano Linfomi Score)

Prognostic Factors of Parry-Jones et al for Splenic Lymphoma with Villous Lymphocytes

Prognostic Model of Low et al for a Patient with Grade II Non-Hodgkin's Lymphoma

Criteria of Quintanilla-Martinez for Fulminant Epstein-Barr Virus (EBV) Positive T-Cell Lymphoproliferative Disorder

Memorial Sloan-Kettering Cancer Center (MSKCC) Prognostic Model for Primary CNS Lymphoma

Nottingham/Barcelona Prediction Score for Primary Non-Hodgkin's Lymphoma of the CNS

Prognostic Factors of Laskar et al for a Patient with Primary Diffuse Large B-Cell Lymphoma of the Tonsil

Criteria of Solal-Celigny et an for High Tumor Burden in a Patient with Malignant Non-Hodgkin's Lymphoma

Colorectal Lymphomatous Polyposis

Cytologic Variants of Mantle Cell Lymphoma

Prognostic Factors of Bosch et al for a Patient with Mantle Cell Lymphoma

Clinical Features of Lymphomatosis Cerebri

Prognostic Factors of the International T-Cell Lymphoma Project for Peripheral T and NK/T Cell Lymphomas

Prognostic Factors of Savage et al for a Patient with an NK/ T-Cell ALK+ Anaplastic Large-Cell Lymphoma (ALCL)

Prognostic Factors of Savage et al for a Patient with an NK/ T-Cell ALK-Negative Anaplastic Large-Cell Lymphoma (ALCL)

When to Consider the Diagnosis of Malignant Lymphoma in a Patient

Clinical Features of Neurolymphomatosis

Factors of Quijano et al Predictive of Leptomeningeal Disease in a Patient with Burkitt’s Lymphoma

Follicular Lymphoma International Prognostic Index 2 (FLIPI2)

Prognostic Genetic Markers of Cady et al for a Primary Central Nervous System (CNS) Lymphoma

Intravascular Large B-Cell Non-Hodgkin's Malignant Lymphoma Presenting as Pulmonary Arterial Hypertension (PAH)

Clinical Features of EBV-Related X-Linked Lymphoproliferative Disease (XLP)

Prognostic Scoring System of Mazloom et al for a Patient with Extranodal Marginal Zone Lymphoma (MZL)

Clinical and Pathological Features of Pyothorax-Associated Lymphoma (PAL)

Clinical and Pathological Features of a Chronic-Inflammation Associated Lymphoma

Risk of AIDS-Related Malignant Lymphoma in a Patient Based on Serum Free Light Chain Concentrations

Chromosomal Abnormalities of Onciu et al Seen in Patients with Burkitt's Lymphoma

Mantle Cell Lymphoma (MCL) International Prognostic Index (MIPI) of Hoster et al

Significance of Lymphocytosis for a Patient with Mantle Cell Lymphoma

Prognostic Factors of Weisenburger et al for a Patient with a Peripheral T-Cell Lymphoma Not Otherwise Specified (PTCL-NOS)

Risk Factors of Cairo et al for Treatment Failure in a Pediatric Patient with a Mature B-Cell Non-Hodgkin’s Lymphoma

Risk Groups of the Berlin-Frankfurt-Munster (BFM) Group for Burkitt Lymphoma

When to Consider the Diagnosis of EBV-Positive Diffuse Large B Cell Lymphoma of the Elderly versus Classic Hodgkin's Disease

Prognostic Model of Huang et al for Extranodal Natural Killer/T-Cell Lymphoma (ENKL)

Prognostic Model of Tanaka et al for HIV-Related Diffuse Large B-Cell Lymphoma (DLBCL) in Brazil

Signet Ring Cell Lymphoma

Malignant Lymphoproliferative Disorders Associated with Acquired Immunodeficiency Syndrome (AIDS)

Plasmablastic Lymphoma in an HIV-Positive Patient

Immunostaining Algorithm of Hans et al for Subdividing Patients with Diffuse Large B-Cell Lymphoma (DLBCL) into Molecular Subtypes

Immunostaining Algorithm of Choi et al for Subdividing Patients with Diffuse Large B-Cell Lymphoma (DLBCL) into Molecular Subtypes

Clinical and Histologic Features of Louissaint et al for Distinguishing Atypical Epstein-Barr Virus (EBV) Lymphoproliferation (Pseudo-Lymphoma) from Malignant Lymphoma

Double or Triple Hit Diffuse Large B-Cell Lymphoma (DLBCL)

Lymph Node Infarction in Malignant Lymphoma

Prognostic Score of the International Prognostic Factors Project for Patients with Advanced Hodgkin's Disease

A Numerical Prognostic Index to Identify Poor Risk Patients with Hodgkin's Disease at Diagnosis

Predictive Equation for Prognosis in Hodgkin's Disease of Gobbi et al

Additional Analysis of Prognosis in Hodgkin's Disease Using the Predictive Equation of Gobbi et al

Estimate for Expected Survival at Diagnosis in Hodgkin's Disease of Gobbi et al

Criteria of the European Organization for Research and Treatment of Cancer Groupe d'Eude des Lymphomes de l'Adulte (EORTC-GELA) for Favorable Prognostic Groups of Hodgkin's Disease

Prognostic Factors of Straus et al for Patients with Advanced Hodgkin's Disease

Prognostic Factors of Wagstaff et al for Patients with Stage IIIB and IV Hodgkin's Disease

Manchester Index of Lee et al for Identifying Risk of Progression in Patients with Hodgkins Disease

Integrated Index of Gobbi et al for Patients with Advanced Hodgkin's Disease

Prognostic Index of Smith et al for Children with Hodgkin's Disease Receiving Combined Modality Therapy

Histologic Grades of MacLennan et al for Nodular Sclerosing Hodgkin's Disease

Prognostic Score of Josting et al for Patients with Relapsed Hodgkin's Lymphoma

Prognostic Score of Sup et al for Patients with Classical Hodgkin's Lymphoma

Prognostic Factors of Wirth et al for a Patient with Lymphocyte Predominant Hodgkin's Disease Treated with Radiation Therapy Alone

Grading Scheme of von Wasielewski et al for Nodular Sclerosing Hodgkin Disease

Clinical Prediction Rule of Vassilakopoulos et al for Predicting Bone Marrow Involvement in a Patient with Hodgkin's Disease

Prognostic Model of Low et al for a Patient with Hodgkin's Disease

Prognostic Scoring System of Maurcort-Boulch et al for a Patient with Hodgkin's Disease

Plasma Cytokine Signature Score of Casasnovas et al for Predicting Outcome in a Patient with Classic Hodgkin's Disease

Transformation of Nodular Lymphocyte-Predominant Hodgkin's Lymphoma to Diffuse Large B-Cell or Other Form of Aggressive Lymphoma

Lahey's Definition of Organ Dysfunction in Histiocytosis X

The Southwest Oncology Group Staging System for Histiocytosis X

Histiocytosis Grouping System of Osband et al.

Factors Predictive of Progressive Disease in Patients with Langerhans Cell Histiocytosis

Criteria for the Diagnosis of Primary Thrombocythemia

Diagnostic Scoring System for Primary Thrombocythemia of Dudley et al

Approach of Schafer for Management of Primary (Clonal) Thrombocythemia

Treatment Algorithm of Tefferi and Barbui for a Patient with Essential Trombocythemia

Risk Classification of Tefferi and Barbui for a Patient with Essential Thrombocythemia

Risk Factors of Wolanskyj et al for Thrombotic Complications in a Patient with Essential Thrombocythemia

Risk Factors of Wolanskyj et al for Mortality in a Patient with Essential Thrombocythemia

Criteria of Campbell and Green for Primary Thrombocythemia Based on JAK2 Status

Recommendations of an Ad Hoc International Expert Panel to Revise the WHO Criteria for Essential Thrombocythemia

The 2001 WHO Criteria for Essential Thrombocythemia

Risk Factors of Carobbio et al for Thrombosis in a Patient with Essential Thrombocythemia

Acute Myocardial Infarction (AMI) in a Patient with Essential Thrombocythemia

Response Criteria of the European LeukemiaNet Following Treatment of Essential Thrombocythemia

Criteria of the European LeukemiaNet for Hydroxyurea Resistance or Intolerance in a Patient with Essential Thrombocythemia

Polycythemia Vera Study Group Criteria for Diagnosis

Criteria of Hoffman and Boswell for Polycythemia Vera

Flow Chart of Barbui and Finazzi for Therapy Selection in Polycythemia Vera

Treatment Algorithm of Tefferi for a Patient with Polycythemia Vera

Risk Classification of Tefferi and Barbui for a Patient with Polycythemia Vera

Criteria of Tefferi and Barbui for the Diagnosis of Polycythemia Vera

Criteria of Campbell and Green for Polycythemia Based on JAK2 Status

Recommendations of an Ad Hoc International Expert Panel to Revise the WHO Criteria for Polycythemia Vera

The 2001 WHO Criteria for Polycythemia Vera

Response Criteria of the European LeukemiaNet Following Treatment of Polycythemia Vera

Criteria of the European LeukemiaNet for Hydroxyurea Resistance or Intolerance in a Patient with Polycythemia Vera

Synthesis Prognostic Staging System of Kantarjian et al for CML

Prognostic Score 1 of Hehlmann et al in CML

Regression Models of Kantarjian et al for Predicting Survival in CML

Relative Risk Equation of Sokal et al for Patients with Chronic Myelogenous Leukemia (CML)

Relative Hazard Equation of Cervantes and Rozman for Patients with Chronic Myelogenous Leukemia (CML)

Prognostic Score of Hasford et al for Patients with Chronic Myeloid Leukemia Treated with Interferon Alfa

Negative Prognostic Factors of the Italian Cooperative Study Group for Staging Chronic Myeloid Leukemia

Morphometric Bone Marrow Risk Classification Method of Kvasnicka et al for Patients with Chronic Phase Philadelphia Chromosome Positive Chronic Myelogenous Leukemia (CML)

Features of Atypical Chronic Myeloid Leukemia (aCML) in the WHO Classification of Mixed Myelodysplastic and Myeloproliferative Disorders

Prognostic Score of Onida et al for Philadelphia Chromosome Negative, bcr/abl Negative Chronic Myelogenous Leukemia (CML)

Criteria of the WHO Classification for the Accelerated and Blastic Phases of Chronic Myelogenous Leukemia (CML)

Criteria for Therapeutic Response in Patients with Chronic Myelogenous Leukemia (CML) in the Chronic or Accelerated Phase

The European Group for Bone Marrow Transplant (EBMT) Risk Score for a Patient with Chronic Myeloid Leukemia Following Marrow or Stem Cell Transplant

The Risk Score of Passweg et al for the First Chronic Phase of CML (CML-CP Score)

Model of Kantarjian et al for Predicting a Complete Cytogenetic Response to Imatinib Mesylate in a Patient with Philadelphia Chromosome Positive Chronic Phase CML

Morphological Score of Lugli et al for Monitoring the Response of a Patient with Chronic Myelogenous Leukemia (CML) to Imatinib Mesylate

Sudden Blast Crisis in a Patient with Philadelphia-Positive Chronic Myelogenous Leukemia (CML)

Chronic Neutrophilic Leukemia (CNL)

Score of Milojkovic et al Predicting Response of a Patient with Chronic Myelogenous Leukemia (CML) to a Second Generation Tyrosine Kinase Inhibitor

Prognostic Groups of Visani et al in Myelofibrosis with Myeloid Metaplasia

Prognostic Score of Hasselbalch and Jensen in Idiopathic Myelofibrosis

Criteria for the Diagnosis of Myelofibrosis with Myeloid Metaplasia

Prognostic Classes of Njoku et al in Myelofibrosis with Myeloid Metaplasia

Factors of Cervantes et al for the Identification of Low and High Risk Prognostic Groups in Idiopathic Myelofibrosis

Prognostic Classification of Barosi et al for Myelofibrosis with Myeloid Metaplasia

Prognostic Factors of Kvasnicka et al for Idiopathic Osteomyelofibrosis

The Lille Scoring System of Dupriez et al for Predicting Survival in Agnogenic Myeloid Metaplasia

Severity Score of Barosi et al for Myelofibrosis with Myeloid Metaplasia (Myelodepletive and Myeloproliferative Indices)

Risk Classification of Tefferi and Barbui for Myelofibrosis with Myeloid Metaplasia

CBC-Based Scoring System of Dingli et al for a Patient with Agnogenic Myeloid Metaplasia

Guidelines of Tefferi and Deeg for Therapy in a Patient with Myelofibrosis and Myeloid Metaplasia

Criteria of Campbell and Green for Myelofibrosis Based on JAK2 Status

Score of Elliott et al for Survival in Primary Myelofibrosis (New Mayo Score)

Recommendations of an Ad Hoc International Expert Panel to Revise the WHO Criteria for Primary Myelofibrosis

WHO Criteria (2001) for the Prefibrotic Stage of Primary Myelofibrosis (PMF)

WHO Criteria (2001) for the Fibrotic Stage of Primary Myelofibrosis (PMF)

Risk Factors of Huang et al for Leukemia Transformation in a Patient with Primary Myelofibrosis

Prognostic Factors of Cervantes et al in a Young Patient with Myelofibrosis and Myeloid Metaplasia

Circulating CD34+ Cells in a Patient with Myelofibrosis with Myeloid Metaplasia

Predictive Factors of Kreft et al for Marrow Fibrosis in a Patient with Pre-Fibrotic Chronic Idiopathic Myelofibrosis

Grading Scheme of Okamura et al for Primary Chronic Myelofibrosis

Prognostic Score of Cervantes et al for Primary Myelofibrosis Based on the IWGMRT

Criteria of Tam et al for an Accelerated Phase (AP) in Myelofibrosis

Dynamic International Prognostic Scoring System (DIPSS) of Passamonti et al for Predicting Survival in Primary Myelofibrosis

DIPSS Plus of Gangat et al for Evaluating a Patient with Primary Myelofibrosis

Cytogenetic Risk Categories of Caramazza et al for a Patient with Primary Myelofibrosis

Prognostic Factors of Barbui et al for a Patient with Essential Thrombocythemia versus Early Primary Myelofibrosis

Clinical and Laboratory Findings of Barbui et al Associated with Progression of Myelofibrosis

Criteria of the International Working Group for Progressive Disease Following Therapy of Myelofibrosis with Myeloid Metaplasia

Sclerosing Extramedullary Hematopoietic Tumor (SEMHT)

Prognostic Model of Gianelli et al for a Patient with Primary Myelofibrosis

Scoring System of Morel et al for Waldenstrom's Macroglobulinemia

Prognostic Score of Gobbi et al for Waldenstrom's Macroglobulinemia

Prognostic Factors of Facon et al for Waldenstrom's Macroglobulinemia

Prognostic Factors and Diagnostic Criteria of Owen et al for Waldenstrom's Macroglobulinemia

Prognostic Score of Baldini et al for Predicting Evolution of Asymptomatic Macroglobulinemia (IgM MGUS or Indolent Waldenstrom's Macroglobulinemia)

Prognostic Models of Ghobrial et al for a Newly Diagnosed Patient with Symptomatic Waldenstrom's Macroglobulinemia

International Prognostic Scoring System (IPSS) for Waldenstrom's Macroglobulinemia

Risk Factors of Kyriakou et al Affecting Overall Survival for a Patient Waldenstrom’s Macroglobulinemia Following Autologous Stem Cell Transplantation

Viscosity in Patients with Leukemia

Hyperviscosity Syndrome in Patients with Leukemia

Leukostasis in Patients with Leukemia

Pseudohypoxemia in Patients with Hyperleukocytosis

Grades of Novotny et al for Symptoms in Hyperleukocytic Leukemia

Tumor Burden Index in Cutaneous T-Cell Lymphoma

TNM Staging of Cutaneous T-Cell Lymphoma

Histopathologic Criteria of Cox for Mycosis Fungoides

The Severity-Weighted Assessment Tool (SWAT) for Mycosis Fungoides

Prognostic Features of Gniadecki et al for CD56-Positive Extranodal Lymphoma with Cutaneous Involvement

Cutaneous B-Cell Lymphoma Prognostic Index of Smith et al

Pseudo-Sezary Syndrome in a Patient with AIDS

Clinical and Laboratory Features of Sezary Syndrome

Grading Lymph Node Involvement in Mycosis Fungoides or Sezary Syndrome

Clinical Features of Primary Cutaneous Diffuse Large B-Cell Lymphoma of the Leg Type

Clinical and Laboratory Features of Subcutaneous Panniculitis-Like T-Cell Lymphoma (SPTCL) with alpha-beta T-Cell Receptors

Clinical and Laboratory Features of Cutaneous gamma-delta T-Cell Lymphoma (Subcutaneous Panniculitis-Like T-Cell Lymphoma with gamma-delta T-Cell Receptors)

Risk Factors of Diamandidou et al for Large Cell Transformation in a Patient with Sezary Syndrome or Mycosis Fungoides

Prognostic Factors of Diamandidou et al for a Patient with Sezary Syndrome or Mycosis Fungoides Undergoing Large Cell Transformation

Clinical Features of Aggressive Primary Cutaneous T-Cell Lymphoma Localized to the Lower Leg

Prognostic Factors of Woo et al for a Patient with Primary Cutaneous Anaplastic Large Cell Lymphoma

Response Criteria of Olsen et al of Mycosis Fungoides and Sezary Syndrome to Therapy: Visceral Involvement

Criteria of Amano et al for HTLV-1 Associated Cutaneous Adult T-Cell Leukemia/Lymphoma (ATLL)

Prognostic Factors of Benner et al for a Patient with Transformed Mycosis Fungoides

Algorithm of Song et al for Early Mycosis Fungoides (MF, Modified Score of Pimpinelli et al)

Conditions Associated with Cutaneous Pseudolymphoma

Acute Tumor Lysis Syndrome in Malignant Lymphoma or Lymphocytic Leukemias

Penn Predictive Score of Tumor Lysis Syndrome (PPS-TLS) in Acute Myelogenous Leukemia

Grading Classification of Cairo and Bishop for the Tumor Lysis Syndrome

Predictive Factors of Truong et al for Tumor Lysis Syndrome in a Pediatric Patient with Acute Lymphoblastic Leukemia (ALL)

Risk Factors of Coiffier et al for Tumor Lysis Syndrome

Risk Stratification of a Patient with the Tumor Lysis Syndrome

Dosing Rasburicase in a Patient at Risk for the Tumor Lysis Syndrome

Treatment of Electrolyte Abnormalities in a Patient with the Tumor Lysis Syndrome

Dosing Allopurinol in a Patient at Risk for the Tumor Lysis Syndrome

Predictive Model of Montesinos et al for the Tumor Lysis Syndrome in a Patient with Acute Myeloid Leukemia

Evaluation of Acute Leukemia with Positive Peroxidase or Sudan Black B Stains

Evaluation of Acute Leukemia Negative for Peroxidase, Sudan Black B and Esterase Stains

Subclassification of Acute Lymphoblastic Leukemia Using Immunocytochemical Stains

The European Group for the Immunological Classification of Leukemias Scoring System for Identification of Biphenotypic Acute Leukemia (BAL)

Scoring System of Thalhammer-Scherrer et al in Adult Acute Leukemia

Scoring System of Moreau et al for Distinguishing CLL from Other B-Cell Lymphoproliferative Disorders

Prognostic Factors of Archimbaud et al in Angioimmunoblastic Lymphadenopathy

Angioimmunoblastic T-Cell Lymphoma (AITL) Prognostic Index of Tokunaga et al.

Symptoms Associated with Plasma Hyperviscosity

Indications for Plasmapheresis in Patients with Plasma Hyperviscosity

Diagnostic Criteria for Hemophagocytic Lymphohistiocytosis

Prognostic Factors for Adults with the Hemophagocytic Syndrome

2004 Update to the Diagnostic Criteria for Hemophagocytic Lymphohistiocytosis (HLH)

Criteria of Ravelli et al for the Macrophage Activation Syndrome (MAS) in a Patient with Systemic Juvenile Idiopathic Arthritis

Clinical and Pathologic Features of Hodgkin Lymphoma-Associated Hemophagocytic Syndrome

EBV-Related Hemophagocytic Lymphohistiocytosis (HLH)

Classification of McDaniel et al for Lymphoproliferative Disorders of Granular Lymphocytes (LDGL)

Algorithm of Lamy and Loughram for Evaluation of Large Granular Lymphocytosis in the Blood

Transient Myeloproliferative Disorder in Newborns with Trisomy 21 (Down Syndrome)

Complications Associated with Transient Myeloproliferative Disorder (Transient Abnormal Myelopoiesis) in a Neonate with Trisomy 21

Grading Scheme of Lipford et al for Lymphomatoid Granulomatosis

Classification Scale of Wotherspoon et al for Gastric MALT Lymphoma

TNM Staging of Gastric Mucosa-Associated Lymphoid Tissue (MALT) Lymphoma

Risk Factors of Curtis et al for Posttransplantation Lymphoproliferative Disorders in Patients After Bone Marrow Transplantation

Criteria of Preiksaitis and Keay for Clonality and Epstein-Barr Virus (EBV) Status in Posttransplant Lymphoproliferative Disorder

Risk Factors of Preiksaitis and Keay for Posttransplant Lymphoproliferative Disorder

Prognostic Score of Ghobrial et al for an Adult with a Solid Organ Transplant and Post-Transplantation Lymphoproliferative Disorder

Prognostic Factors of Evens et al for a Patient with Post-Transplantation Lymphoproliferative Disease (PTLD)

Risk Factors for Posttransplant Lymphoproliferative Disorder (PTLD) in a Renal Transplant Patient Treated with Belatacept (Nulojix)

Prognostic Score of Caillard et al for Post-Transplant Lymphoproliferative Disorder (PTLD)

Prognostic Factors for a Follicular Dendritic Cell Sarcoma/Tumor

Clinical and Laboratory Features of Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)

Immunophenotype of Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)

Clinical Features of Alpha Heavy Chain Disease (Mediterranean Abdominal Lymphoma)

Clinical Features of Gamma Heavy Chain Disease (Franklin's Disease)

Clinical Features of Mu Heavy Chain Disease

Extensive Sarcoid-Like Granulomas in a Patient with a Lymphoproliferative Disorder (Sarcoidosis-Lymphoma Syndrome)

Malignancy-Sarcoidosis Syndrome

Clinical and Laboratory Findings in a Patient with Multicentric Castleman's Syndrome

Histologic Features of Multicentric Castleman's Syndrome

Criteria of Gerard et al for an Attack of Multicentric Castleman's Disease (MCD)

Oncogenetic Risk Classification of Trinquand et al for Adult T-Cell Acute Lymphoblastic Leukemia (T-ALL)

Classification of CNS Status in a Patient with Acute Lymphoblastic Leukemia (ALL)

Interpretation of a Bloody CSF Tap in a Patient Presenting with Acute Lymphoblastic Leukemia (ALL)

Central Nervous System (CNS) Relapse in a Patient with Acute Lymphoblastic Leukemia (ALL)

Prognostic Factors of Mauro et al for a Patient with Early Onset (Age <= 55 Years) Chronic Lymphocytic Leukemia (CLL)

Multiple Myeloma: Interleukins

Multiple Myeloma: RNA Index

Multiple Myelomas: Serum LDH

Multiple Myeloma: Tumor Ploidy

Classification of Wu et al for Primary Effusion-Based Lymphoma (PEL)

Loss of CD20 Expression in B-Cell Malignant Lymphomas Associated with Rituximab Therapy

Prognostic Factors of Orwat and Batalis for a Patient with Intravascular Large B-Cell Lymphoma (IVLBCL)

Prognostic Model of Perry et al for Diffuse Large B-Cell Lymphoma (DLBCL)

Ratio of Absolute Neutrophil to Lymphocyte Counts in Classic Hodgkin's Disease

International Prognostic Score for Essential Thrombocythemia (IPSET) of Passamonti et al

European Treatment and Outcome Study for CML (EUTOS) Score for a Patient Treated with Imatinib

Clinical and Laboratory Findings Associated with Large Granular Lymphocytic Leukemia

Non-Hodgkin’s Lymphoma in Patients Infected with Hepatitis C Virus (HCV)

Prognostic Index in Cytogenetically Normal Acute Myeloid Leukemia (PINA) of Pastore et al for Overall Survival (OS)

Prognostic Index in Cytogenetically Normal Acute Myeloid Leukemia (PINA) of Pastore et al for Relapse-Free Survival (RFS)

Risk Score of Sanz et al for Acute Promyelocytic Lekemia from the PETHEMA and GIMEMA Cooperative Groups

CBC Score of Park et al for Prognosis in Acute Promyelocytic Leukemia (APL)

Immunophenotypic Markers of Poor Prognosis in Acute Promyelocytic Leukemia (APML)

Prognostic Score of Moreau et al for Predicting Early Progression in a Patient with Multiple Myeloma

Aspiration Cytology of the Lower Abdominal Fat Pad in the Diagnosis of Systemic Amyloidosis

Mediastinal Gray Zone Lymphoma (Large B-Cell Lymphoma with Hodgkin Features, Hodgkin-Like Anaplastic Large Cell Lymphoma)

National Comprehensive Cancer Network International Prognostic Index (NCCN-IPI) for a Patient with Diffuse Large B-Cell Lymphoma

Histologic Staging System of Liu et al for Breast Implant-Associated Anaplastic Large Cell Lymphoma (BI-ALCL)

MUM-1 and Ki-67 Expression in Follicular Lymphoma

Anaplastic Large Cell Lymphoma Associated with Breast Implant

Composite Lymphoma

Pyothorax-Associated Lymphoma (PAL)

Prognostic Significance of PET (Positron Emission Tomography) Scan Findings After 1 and 2 Cycles of Chemotherapy for Hodgkin's Disease

Nasopharyngeal Hodgkin's Disease

Granulomatous Slack Skin Syndrome (GSS)

Differential Diagnosis of Hemophagocytic Lymphohistiocytosis (HLH)

Prognostic Score of Nowakowski et al for a Patient with T-Cell Large Granular Lymphocytic Leukemia (LGLL)

Model of Hill et al for Predicting Risk of Progression to Myeloma in a Patient with Solitary Plasmacytoma of Bone

Revised International Staging System (R-ISS) of Palumbo et al for Myeloma

Familial Myeloma

Criteria of Fernandez de Larrea et al for Progression of Plasma Cell Leukemia (PCL, IMWG Criteria)

Criteria of Fernandez de Larrea et al for Relapse of Plasma Cell Leukemia (PCL) After Complete Remission (IMWG Criteria)

Criteria of Fernandez de Larrea et al for Remission of Plasma Cell Leukemia (PCL, IMWG Criteria)

Criteria of Palladini et al for Response to Therapy by a Patient with Immunoglobulin Light Chain Amyloidosis

Enteropathy-Associated T-Cell Lymphoma (EATL) Prognostic Index (EPI) of de Baaij et al

Types of Enteropathy-Associated T-Cell Lymphoma (EATL)

Hodgkin-Like Cells (cHL) in Non-Hodgkin's Lymphoma

Autoimmune Conditions in Patients with Marginal Zone Lymphoma (MZL)

Risk Factors of Jabbour et al for Outcome in a Patient with Ph+ Chronic Myeloid Leukemia (CML) in Chronic Phase Treated with Nilotinib After Imatinib

Prognostic Model of Scarisbrick et al for Patients with Advanced Stage Mycosis Fungoides or Sezary Syndrome

Hydroa Vacciniforme-Like Lymphoma (HVLL)

Indications of Lamy and Loughran to Treat a Patient with Large Granular Lymphocytic Leukemia (LGLL)

Classification for Acute Leukemias of Ambiguous Lineage

Comprehensive Prognostic Index of Pflug et al for a Patient with Chronic Lymphocytic Leukemia (CLL, Model of the German CLL Study Group, GCLLSG)

International Prognostic Index for a Patient with Chronic Lymphocytic Leuekemia (CLL-IPI)

European ALMA Score for a Patient with Acute Myeloid Leukemia (AML) Who Is Treated with Azacitidine

Acute Myeloid Leukemia (AML) Maturity Score of Schneider et al Based on Flow Cytometry

Integrative Prognostic Risk Score (IPRS) of Damm et al for Acute Myeloid Leukemia (AML) with Normal Karyotype

Risk-Adapted Model of Yoon et al for an Older Adult with Acute Myeloid Leukemia (AML)

Model of Mauer et al for Predicting Event-Free Survival at 24 Months for a Patient with Diffuse Large B-cell Lymphoma (DLBCL)

MIPI-c of Hoster et al for Mantle Cell Lymphoma

Predictive Factors of Sarkozy et al for Histologic Transformation in a Patient with Follicular Lymphoma

CNS International Prognostic Index (CNS IPI) of Schmitz et al for a Patient with Diffuse Large B-Cell Lymphoma (DSHNHL Prognostic Model)

Risk Model of Guglielmi et al for a Patient with Diffuse Large Cell Lymphoma at First Relapse

Risk Factors of Olszewski et al for 30-Day Mortality in an Older Adult with Diffuse Large B-Cell Lymphoma (DLBCL) After Rituximab-Based Immunochemotherapy

Prognostic Score of Barta et al for AIDS-Related Lymphoma: HIV Subscore

Prognostic Score of Barta et al for AIDS-Related Lymphoma: Total ARL-IPI

Extranodal Scoring System of Hwang et al for Evaluating a Patient with Diffuse Large B-Cell Lymphoma (DLBCL)

Use of Platelet Count and Serum Albumin to Predict Prognosis for an Elderly Adult with Diffuse Large B-Cell Lymphoma (DLBCL, Platelet-Albumin Score of Ochi et al)

3-Item International Prognostic Score (IPS-3) of Diefenbach et al for a Patient with Hodgkin’s Disease

Features of Appel et al for Low-Risk Pediatric Lymphocyte-Predominant Hodgkin's Lymphoma (LPHL) That Requires Minimal Therapy

Histological Score of Shet et al for Nodular Lymphocyte Predominant Hodgkin Disease

Criteria of Campiotti et al for Blast Crisis in a Patient with Chronic Myeloid Leukemia (CML)

Cells of Origin for a Blast Crisis in a Patient with Chronic Myeloid Leukemia (CML)

Clinical Features of the Bing-Neel Syndrome in a Patient with Waldenstrom's Macroglobulinemia

Criteria for the Diagnosis of the Bing-Neel Syndrome in a Patient with Waldenstrom's Macroglobulinemia

Prognostic Factors of Castillo et al for Bing-Neel Syndrome (BNS) in a Patient with Waldenstrom's Macroglobulinemia

Cutaneous Lymphoma International Prognostic Index (CLIPi) of Benton et al for Mycosis Fungoides and Sezary Syndrome: Model for Early Stage Disease

Cutaneous Lymphoma International Prognostic Index (CLIPi) of Benton et al for Mycosis Fungoides and Sezary Syndrome: Model for Late Stage Disease

HScore of Fardet et al for the Diagnosis of the Reactive Hemophagocytic Syndrome

TAFRO Syndrome (Castleman-Kojima Syndrome)

Prognostic Model of Rollig et al for a Patient with Acute Myeloid Leukemia (AML) with Intermediate-Risk Karyotype

Indications of Grever et al for Therapy of a Patient with Hairy Cell Leukemia (HCL)

Risk Factors of Tam et al for a Patient with Chronic Lymphocytic Leukemia (CLL) with De Novo Deletion of 17p13.1

Simplified Risk Scores of Stephens et al for a Patient with Chronic Lymphocytic Leukemia (CLL) with del(17p13.1): Treatment-Free Survival

Simplified Risk Scores of Stephens et al for a Patient with Chronic Lymphocytic Leukemia (CLL) with del(17p13.1): Overall Survival

Primary Adrenal Lymphoma (PAL)

Models of Fragkioudaki et al for Risk of Non-Hodgkin's Lymphoma in a Patient with Sjogren's Syndrome

Second-Line Age-Adjusted International Prognostic Index (sAAIPI)

Polycythemia Vera Risk Score of Tefferi et al

Risk Factors of Polverelli et al for Infection in a Patient with Myelofibrosis

Clinical Findings of Clarke et al Seen in Pediatric Leukemia

Prognostic Model of Delgado et al for Chronic Lymphocytic Leukemia (CLL)

Day of Blast Disappearance (DOBD) and Other Prognostic Factors of Short et al for Acute Myeloid Leukemia (AML)

Prognostic Groups of the European LeukemiaNet Based on Cytogenetics and Molecular Genetics for Acute Myeloid Leukemia (AML)

Blastic/Blastoid Transformation of Follicular Lymphoma

Clinical Prediction Rule of Baldini et al for Malignant Lymphoma in a Patient with Primary Sjogren's Syndrome

Factors of Solans-Laque et al for Malignant Lymphoma in a Patient with Primary Sjogren's Syndrome

Risk Factors of Baimpa et al for Malignant Lymphoma in a Patient with Primary Sjogren Syndrome

Prognostic Factors of Ioannidis et al for Lymphoproliferative Disorders and Mortality in a Patient with Primary Sjogren's Syndrome

Predictors of Theander et al for Malignant Lymphoma in a Patient with Primary Sjogren's Syndrome

Clinical Findings of Voulgarelis et al Associated with Malignant Lymphoma in a Patient with Primary Sjogren's Syndrome

Spontaneous Regression of a Malignant Hodgkin's or Non-Hodgkin's Lymphoma

Favorable Categories of Sasse et al for Early Hodgkin Disease

International Working Group for Myeloproliferative Research and Treatment (IWG-MRT) Criteria for Post-Essential Thrombocythemia Myelofibrosis

Prognostic Factors of Mudireddy et al for a Patient with Essential Thrombocythemia

Triple-Negative Myeloproliferative Neoplasm (MPN)

International Working Group for Myeloproliferative Research and Treatment (IWG-MRT) Criteria for Post-Polycythemia Vera Myelofibrosis

Criteria of Grever for Progression in Hairy Cell Leukemia (HCL) After Therapy

Hairy Cell Leukemia Variants (Atypical Hairy Cell Leukemia)

Indolent Prognostic Index (iATL-PI) of Katsuya et al for Chronic or Smoldering Adult T-Cell Leukemia/Lymphoma (ATL)

Predictors of Fink et al for a Poor Outcome of a Patient with Chronic Lymphocytic Leukemia (CLL) Following Chemoimmunotherapy

Progression-Risk Score of Gentile et al for Predicting Treatment-Free Survival for a Patient with Early Stage Chronic Lymphocytic Leukemia (CLL)

Risk Factors of Morabito et al for Progression in a Patient with Binet Stage A Chronic Lymphocytic Leukemia (CLL)

Prognostic Model of Morabito et al for Chronic Lymphocytic Leukemia (CLL) Including the Total Serum Light Chain Concentration

Laboratory Score of Cohen et al for Predicting Early Treatment of a Patient with Early Stage Chronic Lymphocytic Leukemia (CLL)

Prognostic Score of Condoluci et al for a Patient with Early Stage Chronic Lymphocytic Leukemia (CLL)

Predictors of Terebelo et al for Early Mortality for a Patient with Multiple Myeloma

Risk Factors of Hsu et al for Early Mortality in a Patient with Recently Diagnosed Multiple Myeloma

Criteria of Usmani et al for Ultra High Risk Multiple Myeloma

CRAB Findings in Multiple Myeloma

Risk Assessment Model of Avet-Loiseau et al for a Patient with Myeloma That Combines ISS Stage and FISH

Revised Criteria of the International Myeloma Working Group (IMWG): Smoldering Multiple Myeloma (SMM)

Criteria for High Risk Smoldering Multiple Myeloma (SMM)

Criteria of the International Myeloma Working Group for IgM MGUS (IgM Monoclonal Gammopathy of Undetermined Significance)

Criteria of the International Myeloma Working Group for Non-IgM MGUS (Non-IgM Monoclonal Gammopathy of Undetermined Significance, IgA or IgG Monoclonal Gammopathy of Undetermined Significance)

Criteria of the International Myeloma Working Group for Light Chain MGUS (Monoclonal Gammopathy of Undetermined Significance)

Criteria of the International Myeloma Working Group for Solitary Plasmacytoma

Criteria of the International Myeloma Working Group for Multiple Myeloma

Immunoparesis in Myeloma

Oral Manifestations of Multiple Myeloma

Criteria of Grogan et al for Organ Involvement in a Patient with Biopsy-Proven Amyloidosis

Primary Intraocular Malignant Lymphoma (PIOL)

5-Point Score (5PS) Score for PET Scan in a Patient with Malignant Lymphoma (Deauville Scale)

Revised Ann Arbor Staging System for Primary Malignant Lymphoma from the Lugano Conference

Criteria for Lymph Node Involvement from the Lugano Conference on Malignant Lymphoma

Criteria for Splenic Involvement from the Lugano Conference on Malignant Lymphoma

Criteria for Hepatic Involvement from the Lugano Conference on Malignant Lymphoma

Criteria for Central Nervous System (CNS) Involvement from the Lugano Conference on Malignant Lymphoma

Criteria for Involvement of "Other" Body Sites from the Lugano Conference on Malignant Lymphoma

Criteria for Complete Therapeutic Response (CR) of a Malignant Lymphoma from the Lugano Conference

Criteria for Partial Therapeutic Response (PR) of a Malignant Lymphoma from the Lugano Conference

Criteria for No Therapeutic Response (Stable Disease) of a Malignant Lymphoma from the Lugano Conference

Criteria for Progression of a Malignant Lymphoma After Therapy from the Lugano Conference

Scoring System of Bachy et al for Evaluating a Patient with Follicular Lymphoma Who Is Treated Initially with Immunochemotherapy (PRIMA-PI)

Prognostic Score of Kong et al for a Patient with Diffuse Large B-Cell Lymphoma (DLBCL)

Prognostic Factors of Wang et al for Gastric Lymphoma

Clinical Score of Choi et al for Langerhans Cell Histiocytosis (LCH)

Response Categories in Langerhans Cell Histiocytosis (LCH)

Mutation-Enhanced International Prognostic Score System (MIPSS70) of Guglielmelli et al for a Patient with Primary Myelofibrosis

Mutation-Enhanced International Prognostic Score System with Cytogenetic Data (MIPSS70-plus) of Guglielmelli et al for a Patient with Primary Myelofibrosis

MIPSS70+ Version 2.0 for Evaluating a Patient with Primary Myelofibrosis

Revised Cytogenetic Risk Stratification of Tefferi et al for Primary Myelofibrosis

Clinical and Laboratory Features of Primary Cutaneous Acral CD8+ T-Cell Lymphoma

Clinical and Laboratory Features of Primary Cutaneous Aggressive Epidermotropic CD8+ Cytotoxic T-Cell Lymphoma

MALT Lymphoma International Prognostic Index (MALT-IPI) of Thieblemont et al

Integrated Mutational and Cytogenetic Model of Rossi et al in Chronic Lymphocytic Leukemia (CLL)

Predictors of Rosinol et al for Malignant Transformation in a Patient with Monoclonal Gammopathy of Undetermined Significance (MGUS)

Criteria of Yabe et al for Hepatosplenic T-Cell Lymphoma (HSTCL)

Prognostic Factors of Yabe et al for Hepatosplenic T-Cell Lymphoma (HSTCL)

Kyota Prognostic Index (KPI) of Kobayashi et al for Diffuse Large B-Cell Lymphoma (DLBCL)

Prognostic Score of Montalban et al for a Patient with Splenic Marginal Zone Lymphoma

Prognostic Model of Chen et al for Diffuse Large B-Cell Lymphoma (DLBCL)

ACA (Age, Comorbidity, Albumin) Index of Miura et al for a Patient with Diffuse Large B-Cell Lymphoma

Prognostic Index of Kang et al for a Patient with Diffuse Large B-Cell Lymphoma (DBLCL)

SIL Index of Tomita et al for a Patient with Diffuse Large B-Cell Lymphoma (DLBCL)

Prognostic Score of Candelaria et al for an Older Adult with Diffuse Large B-Cell Lymphoma (DLBCL)

Inflammation-Based Cumulative Prognostic Score (ICPS) of Sun et al for a Patient with Diffuse Large B-Cell Lymphoma (DLBCL)

Revised International Prognostic Index (R-IPI) for a Patient with Diffuse Large B-Cell Lymphoma

Elderly International Prognostic Index (E-IPI) for a Patient with Diffuse Large B-Cell Lymphoma

AMLPI Prognostic Index of Batty et al for a Patient with Diffuse Large B-Cell Lymphoma (DLBCL)

Prognostic Model of Zhao et al for a Patient with Diffuse Large B-Cell Lymphoma (DLBCL)

Prognostic Index of Matsumoto et al for a Patient with Diffuse Large B-Cell Lymphoma (DLBCL)

Prognostic Model of Salles et al for a Patient with Diffuse Large B-Cell Lymphoma (DLBCL)

ABE3 Score of Prochazka et al for a Patient with Diffuse Large B-Cell Lymphoma (DLBCL)

GELTAMO International Prognostic Index (IPI) for a Patient with Diffuse Large B-Cell Lymphoma (DLBCL)

Comorbidity NCCN-IPI (cNCCN-IPI) of Antic et al for Patients with Diffuse Large B-Cell Lymphoma (DLBCL)

Prognostic Model of Kanemasa et al for a Patient with Diffuse Large B-Cell Lymphoma (DLBCL)

Masked/Prodromal Polycythemia Rubra Vera (PRV)

Genetically Inspired Prognostic Scoring System (GIPSS) of Tefferi et al for Patients with Primary Myelofibrosis

Bone Marrow Fibrosis Associated with Visceral Leishmaniasis (Kala-Azar)

Misdiagnosis of Early Mycosis Fungoides (MF)

Criteria of Kelati et al for Mycosis Fungoides

Criteria of Yabe et al for Large Granular T-Cell Leukemia (LGL)

Prognostic Risk Score of Soumerai et al for Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL, BALL Score)

Modified NCCN-IPI Score of Melchardt et al for an Older Adult with Diffuse Large B-Cell Lymphoma (DLBCL)

HPLL Prognostic Index of Montalban et al for Splenic Marginal Zone Lymphoma

Prognostic Model of Zhu et al for a Patient with Mantle Cell Lymphoma

Prognostic Model of Wilcox et al Using Absolute Monocyte and Lymphocyte Counts in a Patient with Diffuse Large B-Cell Lymphoma (DLBCL)

ABE4 Score of Prochazka et al for a Patient with Diffuse Large B-Cell Lymphoma (DLBCL)

Prognostic Model of Tefferi et al for Postsplenectomy Survival for a Patient with Myelofibrosis

Algorithm of Pimpinelli et al for Early Mycosis Fungoides

Prognostic Model of Hong et al for Angioimmunoblastic T-Cell Lymphoma

Model of Molica et al for Chronic Lymphocytic Leukemia (CLL)

Model of Zhang et al for Predicting Early Death for a Patient with Acute Promyelocytic Leukemia (APML)

Diagnostic Criteria of Valent et al for Basophilic Leukemia

Prognostic Indicators of Jurczyszyn et al for a Patient with Primary Plasma Cell Leukemia

Prognostic Scoring System of Jung et al for a Patient with Myeloma

Prognostic Factors of Kyle et al for Monoclonal Gammopathy of Undetermined Significance (MGUS)

Risk Model of Turesson et al for Progression of Monoclonal Gammopathy of Undetermined Significance (MGUS)

Criteria of Dispenzieri et al for Hematologic Therapeutic Response in a Patient with Light Chain Amyloidosis

Prognostic Criteria of Sachchithanantham et al for Monoclonal IgM-Related Light Chain Amyloidosis

qPET of an Interim FDG-PET Scan for a Patient with Malignant Lymphoma

Prognostic Score of Barrans et a for Diffuse Large B-Cell Lymphoma (DLBCL)

Prognostic Model of Kanemasa et al for CNS Relapse in a Patient with Diffuse Large B-Cell Lymphoma (DLBCL)

Risk Factors of Hollender et al for Central Nervous System (CNS) Involvement in Non-Hodgkin's Lymphoma

Prognostic Indices of Gang et al for a Patient with Diffuse Large B-Cell Lymphoma (DLBCL-PI)

Nomogram of Maurer et al for Overall Survival for a Patient with Diffuse Large B-Cell Lymphoma (DLBCL) Following Frontline Immunochemotherapy

International Pediatric Non-Hodgkin Lymphoma (IPNHL) Staging System

Criteria of Engert et al for Early-Stage Hodgkin's Lymphoma

Staging Classification of Carbone et al for Hodgkin's Disease

Monocytosis in Primary Myelofibrosis

ISCL/EORTC TNM Classification for Primary Cutaneous Lymphoma Other Than Mycosis Fungoides or Sezary Syndrome

CLL Score of Matutes et al

Prognostic Factors of Li et al for Chronic Lymphocytic Leukemia (CLL) in a Chinese Patient

Survival Risk Score for Ibrutinib (SRSI) of Gentile et al for a Patient with Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)

Prognostic Model of Ma et al for an Adult Patient with Acute Myeloid Leukemia (AML)

Hematopoietic Score of Al Saleh et al for a Patient with Newly Diagnosed Multiple Myeloma

Red Cell Distribution Width (RDW) and Prognosis for a Patient with Light Chain Amyloidosis

Clinical Red Flags of Mendelson et al for Light Chain Amyloidosis in a Patient with Myeloma

Amyloid Arthropathy

Diagnostic Criteria of Matutes et al for Splenic Marginal Zone Lymphoma (SMZL)

L-GPS Score of Jung et al for Diffuse Large B-Cell Lymphoma (DLBCL)

Chinese Prognostic Index for Natural Killer Cell Lymphoma (C-PINK) of Hong et al

Prognostic Indices of Kim et al for Natural Killer Cell Lymphoma (PINK, PINK-E)

Prognostic Score of Liu et al for Newly Diagnosed Primary CNS Lymphoma (Taipei Score)

EUTOS Long-Term Survival (ELTS) Score of Pfirrmann et al

Infiltration of the Bone Marrow in Angioimmunoblastic T-Cell Lymphoma

Modified MALT-IPI Score of Kim et al Incorporating Serum Beta-2-Microglobulin (MALT-IPI-B)

Criteria of the All Japan TAFRO Syndrome Research Group for TAFRO Syndrome

Disease Severity Classification of the All Japan TAFRO Syndrome Research Group for TAFRO Syndrome

Prognostic Model of Ahn et al for a Patient with Chronic Lymphocytic Leukemia (CLL) Treated with Ibrutinib (CLL4 Model)

Molecular Criteria of Rossi et al for Predicting Response of a Patient with Chronic Lymphocytic Leukemia (CLL) to Chemotherapy

Chronic Lymphocytic Leukemia (CLL) Associated Liver Dysfunction

CLL1-PM Prognostic Model of Hoechstetter and the German CLL Study Group for Newly Diagnosed CLL Patients in Binet Stage A

International Prognostic Score for Early Stage Chronic Lymphocytic Leukemia (IPS-E)

Simplified CONUT Score of Senjo et al for an Elderly Patient with Acute Myeloid Leukemia (AML)

Prognostic Index of Tachibana et al for a Patient with Relapsed or Refractory Acute Myeloid Leukemia (AML) Undergoing Hematopoietic Stem Cell Transplantation (HSCT)

Myeloid Sarcoma (Granulocytic Sarcoma, Chloroma)

Prognostic Model of Chavda et al for a Myeloma Patient Who Relapses After Upfront Autologous Stem Cell Transplantation

Myeloma Spine and Bone Damage Score (MSBDS) of Tagliafico et al

Chronic Conditions Associated with Secondary Amyloidosis

Disease Severity Score of Damy et al for Hereditary Transthyretin Amyloidosis (ATTRv): Cardiac and Cardiovascular Involvement

Disease Severity Score of Damy et al for Hereditary Transthyretin Amyloidosis (ATTRv): Noncardiac and Nonnneurologic Manifestations

Disease Severity Score of Damy et al for Hereditary Transthyretin Amyloidosis (ATTRv): Sensory Findings

Disease Severity Score of Damy et al for Hereditary Transthyretin Amyloidosis (ATTRv): Motor Function

Disease Severity Score of Damy et al for Hereditary Transthyretin Amyloidosis (ATTRv): Total Score

Amyloidosis and the Underlying Protein

Prognostic Score of Bento et al for a Patient with Diffuse Large B-Cell Lymphoma (DLBCL) Treated with R-CHOP

Prognostic Model of Federico et al for Peripheral T-Cell Lymphoma Not Otherwise Specified (PTCL-NOS)

Prognostic Index of Durot et al for Transformed Waldenstrom's Macroglobulinemia

Histologic Transformation of (Transformed) Waldenstrom's Macroglobulinemia

Revised International Prognostic Score for Waldenstrom's Macroglobulinemia. Leukemia (rIPSSWM)

Predictive Model of Vallapureddy et al for Leukemic Transformation from Primary Myelofibrosis

Prognostic Factors of Tefferi et al for Blast Phase Myeloproliferative Neoplasm (MPN-BP)

Mayo Clinic Revised Criteria for the Diagnosis of Plasma Cell Leukemia (PCL)

Follicular Lymphoma Evaluation Index (FLEX) of Mir et al

Prognostic Model of Lee et al for an Older Adult with Diffuse Large B Cell Lymphoma (DLBCL)

Nomogram of Han et al for Predicting Overall Survival for a Patient with Diffuse Large B-Cell Lymphoma (DLBCL)

Nomogram of Lu et al for Overall Survival of Patient with Burkitt Lymphoma

Prognostic Score of Fanale for Nodular Lymphocyte Predominant Hodgkin Lymphoma (NLPHL)

Childhood Hodgkin International Prognostic Score (CHIPS) of Schwartz et al

Prognostic Model of Huang et al for a Patient with Angioimmunoblastic T-Cell Lymphoma (AITL Risk Index, AITLI))

Acute Lymphoblastic Leukemia (ALL) with MEF2D Rearrangement

Alternative InternationalPrognostic Index-E (AIPS-E) for Binet A Chronic Lymphocytic Leukemia (CLL)

Flow Cytometry Score of Kohnke et al for Chronic Lymphocytic Leukemia (CLL)

Immune Risk Score of Wang et al for a Patient with Acute Myeloid Leukemia (AML) Receiving Chemotherapy

Nomogram of Wang et al for Predicting Survival of a Patient with Acute Myeloid Leukemia (AML) Receiving Chemotherapy

Early Relapse After Autologous Stem Cell Transplant and Prognosis for a Patient with Myeloma

Risk Stratification Scores of Hajek et al for Relapsed Multiple Myeloma: Disease Aggressiveness Risk Score

Risk Stratification Scores of Hajek et al for Relapsed Multiple Myeloma: Frailty Risk Score and Total Risk Score

Elderly Prognostic Index (EPI) of Spina et al for an Older Adult with Diffuse Large B-Cell Lymphoma (DLBCL)

TRAIL Score of Harris et al for Predicting Immunochemotherapy Tolerability for a Patient with Diffuse Large B-Cell Lymphoma (DLBCL)

Burkitt Lymphoma International Prognostic Index (BL-IPI)

Prognostic Nomogram of Shen et al for a CD5-Positive Diffuse Large B-Cell Lymphoma (DLBCL)

HLAMA Score of Gao et al for Gastrointestinal Diffuse Large B-Cell Lymphoma (DLBCL)

Immune Risk Score of Ma et al for Diffuse Large B-Cell Lymphoma (DLBCL)

Nomogram of Fan et al for Predicting Survival in a Patient with Intestinal Diffuse Large B-Cell Lymphoma (DLBCL)

Nomogram of Ma et al for Diffuse Large B-Cell Lymphoma (DLBCL)

Secondary Intraocular Lymphoma (SIOL)

Nomogram of Zhong et al for Evaluating a Patient with Aggressive Non-Hodgkin's Lymphoma

Prognostic Nomogram of Cai et al for a Patient with Diffuse Large B-Cell Lymphoma (DLBCL) in the Rituximab Era

Severe Iron Deficiency Anemia Masking Polycythemia Rubra Vera (PRV)

Signs and Symptoms in Patients with Polycythemia Rubra Vera (PRV)

Three-Factor Model (CLL3) of Molica et al for Chronic Lymphocytic Leukemia (CLL)

Predictors of Lancman et al for Patients in the Blast Phase of Myeloproliferative Neoplasms

Prediction Model of Osterroos et al for Predicting Early Mortality in Acute Promyelocytic Leukemia

Score of Cai et al for Prediction of Early Death for a Patient with Acute Promyelocytic Leukemia (APML)

Modified Sanz Model of Lou et al for a Patient with Newly Diagnosed Acute Promyelocytic Leukemia

Triple-Class Refractory (TCR) Multiple Myeloma

Double and Triple Hit Cytogenetics in Multiple Myeloma

Myeloma Research Alliance Risk Profile (MRP) of Cook et al for Transplant-Ineligible Patients

Orthopedic Changes in Amyloidosis

Prognostic Factors of Gao et al for Primary CNS Lymphoma

Beta2-Microglobulin to Lymphocyte Ratio Index (betaLRI)

Prognostic Model of Dai et al for Extranodal NK/T-Cell Lymphoma (ENKTL)

Hemoglobin-Platelet Index (HPI) of Taniguchi et al for a Patient with Diffuse Large B-Cell Lymphoma (DLBCL)

Algorithm of Nabhan et al for Evaluating a Patient with Chronic Lymphocytic Leukemia (CLL)

Criteria of Popov et al for a Pediatric Patient with ALL Who Can Be Cured with Low-Intensity Therapy

Prognostic Score of Li et al for a Pediatric Patient with Acute Myeloid Leukemia (AML)

Three Factor Model of Tefferi et al for a Patient with Acute Myeloid Leukemia (AML)

Prognostic Model of Li et al for Pediatric Acute Myeloid Leukemia

Predictors of McQuilten et al for Early Mortality for a Patient with Multiple Myeloma

Prognostic Score of Yang et al for Newly Diagnosed Multiple Myeloma with 1q+

Blastic Transformation of Mantle Cell Lymphoma (MCL)

SALENTO Limited Stage Peripheral T-Cell Lymphoma (PTCL) Prognostic Model of Hapgood et al

Nomogram of Wang et al for Predicting Survival of a Patient with Limited Stage Upper Aerodigestive Tract Extranodal Natural/T-Cell Lymphoma Nasal Type (ENKTCL)

Prognostic Factors of Wang et al for a Patient wit Extranodal Natural Killer/T-cell Lymphoma (ENKTL) Nasal Type

Use of Ki-67 Immunostaining to Distinguish Classic from Blastoid Mantle Cell Lymphoma (MCL)

International T-Cell Index of Vose for a Patient with a Peripheral T-Cell Lymphoma (PTCL)

Treatment Algorithm of Ramazanoglu et al for Spinal Lymphoma

Nomogram of Liang et al for Predicting Overall Survival for a Patient with Hodgkin's Disease

Model of Yhim et al for Risk Stratification of Relapsed or Refractory Hodgkin's Disease

Score of Zhang et al for Predicting Failure-Free Survival for a Patient with Chronic Myeloid Leukemia (CML) Treated with Imatinib

Mycosis Fungoides and Sezary Syndrome with Colonization by Staphylococcus aureus

Mutations Associated with Primary Hemophagocytic Lymphohistiocytosis

Screening Score of Li et al for Epstein-Barr Virus Related Hemophagocytic Lymphohistiocytosis (EBV-HLH)

Oncology: Hematologic